AKT1 and neoplasm: Found in 30–40% of cases, these mutations promote persistent activation of oncogenic pathways such as MAPK/ERK and PI3K/AKT, contributing to tumor growth, poor prognosis, and reduced responsiveness to anti-EGFR therapies.